Why the study?
Lifelong oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation is associated with inappropriate dosing, nonadherence, and adverse effects, prompting site-specific left atrial appendage occlusion.
Does left atrial appendage occlusion prevent stroke in patients with nonvalvular atrial fibrillation?
Does left atrial appendage occlusion prevent stroke in patients with nonvalvular atrial fibrillation?
This review summarizes the literature on the risk-balance ratio of left atrial appendage occlusion as an alternative to lifelong oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
Evidence on LAAO risk-balance remains limited; leaves open need for definitive trials versus anticoagulation in nonvalvular AF.
Oral anticoagulation is the dominant strategy for stroke prevention in patients with nonvalvular atrial fibrillation. However, lifelong oral anticoagulation is associated with major issues including inappropriate dosing, nonadherence, and adverse effects. Therefore, efforts have been made to develop site-specific therapy aimed to occlude the left atrial appendage, the anatomical site accountable for more than 90% of nonvalvular atrial fibrillation-related ischemic strokes. This review focuses on the growing literature to put into perspective the risk-balance ratio of left atrial appendage occlusion.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: